FY2022 · ended Dec 31, 2022 · Revenue $45,000 · Filed Mar 15, 2024
Calidi Biotherapeutics, Inc. (CLDI) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). As of Jun 30, 2026 it held $4.1 million in cash and investments and $1.9 million in total debt.
Revenue
$45,000
Net income
$-19.91M
+10.1% vs prior year
Operating cash flow (TTM)
$-17.75M
+20.7% vs year-ago TTM
Free cash flow
—
EPS
$-5.95
+83.3% vs prior year
Dividend per share
None
Shares outstanding
10.90M
-61.7% vs prior year
Net cash
$2.13M
as of Jun 30, 2026
Operating margin
-51395.6%
FY 2022
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- CLDI (NYSE), CLDWW (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1855485
- Former names
- Calidi Biotherapeutics, Inc. (until Sep 25, 2026); First Light Acquisition Group, Inc. (until Sep 19, 2023)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
|---|---|---|---|---|
| Revenue | — | — | — | $45,000 |
| Operating income | -$20.2M | -$21.8M | -$29.0M | -$23.1M |
| Net income | -$19.9M | -$22.1M | -$29.2M | -$25.4M |
| Diluted EPS | -$5.95 | -$35.70 | -$17.33 | — |
| Operating cash flow | -$21.3M | -$19.7M | -$27.0M | -$13.2M |
| Total assets | $8.9M | $14.2M | $10.0M | $2.6M |
| Total liabilities | $5.1M | $12.2M | $18.3M | $43.4M |
| Stockholders' equity | $3.8M | $1.5M | -$8.2M | -$50.4M |
| Cash and investments | $5.6M | $9.6M | $1.9M | $372,000 |
| Total debt | $2.6M | $6.5M | $6.4M | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Listing notice, Other events
|
Sep 25, 2026 | Sep 21, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
Sep 22, 2026 | Sep 17, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 13, 2026 | Aug 13, 2026 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change
|
Jul 31, 2026 | Jul 27, 2026 |
| 8-K |
Current report
Material agreement, Agreement ended, New debt
|
Jul 16, 2026 | Jul 10, 2026 |
All 406 Calidi Biotherapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.